Rheumatoid Arthritis
Conditions
Keywords
microbial dysbiosis, rheumatoid arthritis, dietary factors
Brief summary
The MyRA study will primarily investigate whether there are associations between the structure and function of the gut microbiome and response to methotrexate in early rheumatoid arthritis patients. The microbiome will be characterised via shotgun metagenomic sequencing of microbial DNA present in stool samples taken during the participant's first 6 months of taking methotrexate.
Detailed description
Methotrexate is often the first drug of choice for patients with early rheumatoid arthritis (RA), but its efficacy is highly variable and it can lead to severe side effects. There are currently no reliable predictors of methotrexate efficacy for people with early RA. Microbial dysbiosis (an imbalanced microbiome) has recently been implicated in RA, with associations between specific microbes and RA biomarkers or disease activity. Gut microbes have extensive capabilities in terms of xenobiotic (e.g. drug) metabolism. Several gut microbes are able to alter the drug methotrexate in vitro, and it is possible this could effect drug efficacy in vivo. Alternatively methotrexate efficacy could be affected by baseline microbial composition or alterations to microbial composition over the course of treatment.
Interventions
None listed
Sponsors
Action Arthritis
University of East Anglia
Norfolk and Norwich University Hospitals NHS Foundation Trust
Quadram Institute Bioscience
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* 18-65 years of age * RA diagnosis based on ACR 2010 classification criteria with symptoms starting within the last 2 years * Referred by GP to the Early Arthritis Clinic at the Norfolk and Norwich University Hospitals NHS trust * Commencing methotrexate monotherapy for the first time
Exclusion criteria
* Initially commencing combination therapy (prior to first stool sample) rather than methotrexate monotherapy i.e. MTX combined with another DMARD or prednisolone * Commencement of MTX therapy prior to first stool sample or cessation of MTX therapy at any point during the study * History of psoriasis * Those currently suffering from, or have ever suffered from, any diagnosed gastrointestinal disease, gastrointestinal disorders including regular diarrhoea and constipation (excluding hiatus hernia unless symptomatic) and/or have undergone gastrointestinal surgery. * Those regularly (3+ times/week) taking self-prescribed over the counter medications for digestive/gastrointestinal conditions * Use of laxatives within 7 days prior to sampling unless these have been used on a regular basis (3+ times/week) for more than one month prior to the study and will continue to be used throughout the study period * The use of over-the-counter medications or food/drinks containing pre and/or probiotics within 7 days prior to sampling, unless these have been used on a regular basis (3+ times/week) for more than one month prior to the study and will continue to be used throughout the study period * Significant alteration of the participant's normal diet at any point during the study (e.g. adoption of the 5:2 fasting diet) * Regular (3+ times/week) or recent (within 3 months) use of colonic irrigation or other bowel cleansing techniques * Recently returned to the UK following a period abroad, and who have suffered gastric symptoms during the period abroad or on return to the UK. These will be assessed on an individual basis * Currently taking or finished a course of antibiotics within the last 3 months * Currently pregnant or lactating * Living with or related to any member of the Study Team * Those who have limited or no understanding of spoken and written English
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in DAS28-CRP score | 0-6 months | Disease Activity Score using 28 joints and C-reactive Protein |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in SDAI score | 0-6 months | Simplified Disease Activity Index |
| Concentration of CRP in blood | 0-6 months | C-reactive Protein (an inflammatory biomarker) |
| ESR value (blood) | 0-6 months | Erythrocyte Sedimentation Rate (an inflammatory biomarker) |
| Concentration of anti-CCP in blood | 0-6 months | Anti-Cyclic Citrullinated peptide (disease-specific antibody) |
| Concentration of RF in blood | 0-6 months | Rheumatoid Factor (disease-specific antibody) |
Countries
United Kingdom
Outcome results
None listed